Hersteller |
MedChem Express
|
Kategorie |
|
Typ |
Inhibitors |
Specific against |
other |
Menge |
10mg |
ArtNr |
HY-10219-10mg |
Targets |
mTOR; FKBP; Fungal; Autophagy; Endogenous Metabolite; Antibiotic |
CAS-Nr. |
53123-88-9 |
eClass 6.1 |
30220300 |
eClass 9.0 |
32160605 |
Lieferbar |
|
Product Description |
Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant. |
StorageTemperature |
Powder -20°C 3 years, 4°C 2 years; In solvent -80°C 6 months, -20°C 1 month |
Formula |
C51H79NO13 |
Citations |
Nature. 2021 Jun; 594(7862):271-276. | Nature. 2018 Jun; 558(7711):540-546. | Nature. 2016 Dec 1; 540(7631):119-123. | Cancer Cell. 2021 Mar 8; 39(3):380-393.e8. | Cell Metab. 2021 Nov 2; 33(11):2247-2259.e6. |
References |
[1].Edwards SR, et al. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem, 2007, 282(18), 13395-13401. | [2].Rangaraju S, et al. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathicmice. J Neurosci. 2010 Aug 25; 30(34):11388-97. | [3].Niu H, et al. Rapamycin potentiates cytotoxicity by RP-56976 possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res. 2011 Mar 10; 30:28. | [4].Zhang JW, et al. Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo. Oncol Lett. 2018 Feb; 15(2):1811-1816. |
MolecularWeight |
914.17 |
CompoundPurity |
98.0% |
SMILES |
O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O |
Clinical Information |
Launched |
Research Area |
Cancer |
Solubility |
DMSO : 125 mg/mL (136.74 mM; Need ultrasonic) | Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic) |
Isoform |
mTOR; Autophagy; Human Endogenous Metabolite |
Pathway |
PI3K/Akt/mTOR; Apoptosis; Autophagy; Immunology/Inflammation; Anti-infection; Metabolic Enzyme/Protease |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.